THE Therapeutic Goods Administration (TGA) announced it has granted a second provisional determination for the Novavax COVID-19 vaccine, this morning, which will allow patients aged 12 years and older to receive the jab.
The vaccine received the green-light for patients aged 18 years and older earlier this year (PD 20 Jan), with the rollout getting underway last month (PD 21 Feb), with the TGA noting that Biocelect Pty Ltd is expected to submit an application for provisional registration of the vaccine for adolescents next month.
The TGA added that it anticipates that an application for the vaccine's use in children aged five to 11 years will be lodged later this year.
TGA Head, Adjunct Professor John Skerritt, told a Pharmacy Guild of Australia webinar last week that the vacccine sponsor had also made a submission to have the shot listed as a booster.
At the time Skerritt said a decision on the booster could be made before the end of this month, but added that "the ball is still in Novavax's court, because you've got to have the data before we can assess it" (PD 03 Mar).
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Mar 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Mar 22
